
Evommune, Inc.: updates and filings
Price
$7.04
November 20, 2026Market cap $291M
What Ploutos Investor adds for Evommune
Part of Ploutos Investor, €9.99 a month
- The full history: 2 fiscal years, from 2024
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 12, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
- 17TuePeopleOfficer or director changeDocument
- 12ThuReportQuarterly report · for the period to Sep 30, 2026Document
- 12ThuResultsResults of operations, Regulation FD disclosureDocument
- 4WedDealMaterial agreement entered, unregistered sale of shares, Regulation FD disclosure, other material eventsDocument
August 2026
June 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 17, 2026Officer or director changeForm8-K
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 12, 2026Results of operations, Regulation FD disclosureForm8-K
- Nov 10, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Nov 5, 2026Regulation FD disclosureForm8-K
- Nov 4, 2026Material agreement entered, unregistered sale of shares, Regulation FD disclosure, other material eventsForm8-K
- Oct 1, 2026Regulation FD disclosureForm8-K
- Sep 23, 2026Regulation FD disclosureForm8-K
- Sep 15, 2026Regulation FD disclosureForm8-K
- Sep 9, 2026Regulation FD disclosure, other material eventsForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- Jul 30, 2026Regulation FD disclosureForm8-K
- Jul 16, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jun 29, 2026Regulation FD disclosure, other material eventsForm8-K
- Jun 2, 2026Shareholder voteForm8-K
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 7, 2026Results of operations, Regulation FD disclosureForm8-K
- Apr 24, 2026FilingFormEFFECT
- Apr 22, 2026Correspondence with the SECFormCORRESP
- Apr 22, 2026Letter from the SECFormUPLOAD
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 17, 2026 | 8-K | Officer or director change | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 12, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 12, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Nov 10, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Nov 5, 2026 | 8-K | Regulation FD disclosure | Document |
| Nov 4, 2026 | 8-K | Material agreement entered, unregistered sale of shares, Regulation FD disclosure, other material events | Document |
| Oct 1, 2026 | 8-K | Regulation FD disclosure | Document |
| Sep 23, 2026 | 8-K | Regulation FD disclosure | Document |
| Sep 15, 2026 | 8-K | Regulation FD disclosure | Document |
| Sep 9, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Jul 30, 2026 | 8-K | Regulation FD disclosure | Document |
| Jul 16, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jun 29, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Jun 2, 2026 | 8-K | Shareholder vote | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 7, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Apr 24, 2026 | EFFECT | Filing | Document |
| Apr 22, 2026 | CORRESP | Correspondence with the SEC | Document |
| Apr 22, 2026 | UPLOAD | Letter from the SEC | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 7, 2025.
The full analysis
What do Evommune's filings show?
The filings are where every one of Evommune's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.